基本信息
浏览量:16
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
My academic training in basic biology coupled with extensive technical training in mass spectrometry-based proteomics, next generation sequencing and molecular biology provides me with an excellent background to identify novel avenues to manage cancer and contribute to improving human health. My academic and research training over the last ten years have largely focused on understanding cellular pathways involved with tumor progression. During my doctoral research under mentorship of Dr. Gopal Kundu, I was the first author of the study that identified a key regulatory signaling loop between hypoxia inducible factor 1 and extracellular matrix protein, osteopontin (OPN) that contributed to breast tumor angiogenesis. Subsequently, I was one of lead authors of the study that first reported the role of OPN in tumor infiltrating macrophages and its contribution to melanoma growth. Later I joined Institute of Bioinformatics (IOB) for my postdoctoral training where I was trained in quantitative mass spectrometry-based approaches to identify differentially regulated global signaling networks in lung cancer and head and neck squamous cell carcinomas under Dr. Aditi Chatterjee. I was selected for a prestigious postdoctoral fellowship from Department of Biotechnology, India for my initial two years of training and later on was supported by a Young Investigator Award from the Department of Science and Technology, India to continue my research at IOB. During this period, I started working with Dr. Akhilesh Pandey, under him I took the lead on a multi-omics project that employed an integrated exome, RNA sequencing, and proteomics approach to derive molecular signatures in cancer. As a part of the study, I employed CRISPR-Cas9 system to generate isogenic cell line models to study kinase targets of PTPN7 and PTPN18 phosphatases in the context of cancer. During my postdoctoral tenure at IOB, I successfully employed mass spectrometry, next generation sequencing and in vivo mouse models to identify actionable targets, particularly in HNSCC and lung cancer. My continued interests in 'omics' technologies and immunology led me to choose Dr. Marion Curtis as my mentor for the next stage in scientific training. Dr. Curtis is an early-stage investigator who has successfully conducted innovative studies that led to identification of tumor antigen CT45 in ovarian cancer. My research work at Mayo Clinic focuses on strategies to improve immune response in ovarian cancer. Towards this, I am employing a two-pronged approach wherein firstly, I will build on my previous training in cancer biology and cell signaling to identify targetable pathways that augment anti-tumor immune response against ovarian cancer. By leveraging my background in proteomics and next generation sequencing, I am working on neo-peptide antigen discovery towards the long-term goal of developing effective vaccines against ovarian cancer.
研究兴趣
论文共 54 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCER RESEARCHno. 7 (2023)
Cancer Researchno. 7_Supplement (2023): 4455-4455
Remya Raja,Kristina Butler,Marion Curtis,Paul Magtibay,Esen Yonca Bassoy, Tom Rubino,Fabian Coscia, Krista Goergen,Brenda Ernst, Alessandra Schmitt,Ann Oberg
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
JOURNAL OF IMMUNOLOGYno. 1 (2022)
Omics : a journal of integrative biologyno. 9 (2021): 605-616
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn